_id
6911c33bccc777a4e85d645a
Ticker
HCM
Name
HUTCHMED DRC
Exchange
NASDAQ
Address
Cheung Kong Center, Hong Kong, Hong Kong
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://www.hutch-med.com
Description
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Last Close
13.6
Volume
14280
Current Price
13.55
Change
-0.3676470588235216
Last Updated
2025-12-01T08:43:46.275Z
Image
-
Ipo Date
2016-03-17T00:00:00.000Z
Market Cap
2478332928
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9
Sentiment Sources
10
Rating
4.4286
Target Price
22.5434
Strong Buy
9
Buy
2
Hold
3
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
138838500
Cost Of Revenue
83788500
Gross Profit
55050000
Operating Expenses
56807000
Operating Income
-1757000
Interest Expense
-
Pretax Income
259358500
Net Income
227477000
Eps
1.3034967466187686
Dividends Per Share
-
Shares Outstanding
171867743
Income Tax Expense
31581000
EBITDA
1302000
Operating Margin
-1.265499123081854
Total Other Income Expense Net
261115500
Cash
1364520000
Short Term Investments
1254926000
Receivables
146967000
Inventories
-
Total Current Assets
1592327000
Property Plant Equipment
94573000
Total Assets
1775940000
Payables
43725000
Short Term Debt
29700000
Long Term Debt
93444000
Total Liabilities
534017000
Equity
1229064000
Depreciation
3059000
Change In Working Capital
-15654000
Cash From Operations
-36447000
Capital Expenditures
4633500
Cash From Investing
8796500
Cash From Financing
4660500
Net Change In Cash
-
PE
5.4415
PB
1.9239436043200355
ROE
18.508149290842464
ROA
12.808822370125117
FCF
-41080500
Fcf Percent
-0.2958869477846563
Piotroski FScore
2
Health Score
73
Deep Value Investing Score
7.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
10
Garp Investing Score
3.5
Growth Investing Score
2
Momentum Investing Score
4.5
Net Net Investing Score
2
Quality Investing Score
6
Value Investing Score
8.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
138838500
Quarters > 0 > income Statement > cost Of Revenue
83788500
Quarters > 0 > income Statement > gross Profit
55050000
Quarters > 0 > income Statement > operating Expenses
56807000
Quarters > 0 > income Statement > operating Income
-1757000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
259358500
Quarters > 0 > income Statement > net Income
227477000
Quarters > 0 > income Statement > eps
1.3034967466187686
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
174512902
Quarters > 0 > income Statement > income Tax Expense
31581000
Quarters > 0 > income Statement > EBITDA
1302000
Quarters > 0 > income Statement > operating Margin
-1.265499123081854
Quarters > 0 > income Statement > total Other Income Expense Net
261115500
Quarters > 0 > balance Sheet > cash
1364520000
Quarters > 0 > balance Sheet > short Term Investments
1254926000
Quarters > 0 > balance Sheet > receivables
146967000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
1592327000
Quarters > 0 > balance Sheet > property Plant Equipment
94573000
Quarters > 0 > balance Sheet > total Assets
1775940000
Quarters > 0 > balance Sheet > payables
43725000
Quarters > 0 > balance Sheet > short Term Debt
29700000
Quarters > 0 > balance Sheet > long Term Debt
93444000
Quarters > 0 > balance Sheet > total Liabilities
534017000
Quarters > 0 > balance Sheet > equity
1229064000
Quarters > 0 > cash Flow > net Income
227477000
Quarters > 0 > cash Flow > depreciation
3059000
Quarters > 0 > cash Flow > change In Working Capital
-15654000
Quarters > 0 > cash Flow > cash From Operations
-36447000
Quarters > 0 > cash Flow > capital Expenditures
4633500
Quarters > 0 > cash Flow > cash From Investing
8796500
Quarters > 0 > cash Flow > cash From Financing
4660500
Quarters > 0 > cash Flow > net Change In Cash
-
Quarters > 0 > ratios > PE
1.3034967466187686
Quarters > 0 > ratios > PB
1.9239436043200355
Quarters > 0 > ratios > ROE
18.508149290842464
Quarters > 0 > ratios > ROA
12.808822370125117
Quarters > 0 > ratios > FCF
-41080500
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
-0.2958869477846563
Quarters > 0 > health Score
73
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
138838500
Quarters > 1 > income Statement > cost Of Revenue
83788500
Quarters > 1 > income Statement > gross Profit
55050000
Quarters > 1 > income Statement > operating Expenses
56807000
Quarters > 1 > income Statement > operating Income
-1757000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
259358500
Quarters > 1 > income Statement > net Income
227477000
Quarters > 1 > income Statement > eps
1.3034967466187686
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
174512902
Quarters > 1 > income Statement > income Tax Expense
31581000
Quarters > 1 > income Statement > EBITDA
1302000
Quarters > 1 > income Statement > operating Margin
-1.265499123081854
Quarters > 1 > income Statement > total Other Income Expense Net
261115500
Quarters > 1 > balance Sheet > cash
110719000
Quarters > 1 > balance Sheet > short Term Investments
1254926000
Quarters > 1 > balance Sheet > receivables
146967000
Quarters > 1 > balance Sheet > inventories
48454000
Quarters > 1 > balance Sheet > total Current Assets
1592327000
Quarters > 1 > balance Sheet > property Plant Equipment
94573000
Quarters > 1 > balance Sheet > total Assets
1775940000
Quarters > 1 > balance Sheet > payables
43725000
Quarters > 1 > balance Sheet > short Term Debt
29700000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
534017000
Quarters > 1 > balance Sheet > equity
1229064000
Quarters > 1 > cash Flow > net Income
227477000
Quarters > 1 > cash Flow > depreciation
3059000
Quarters > 1 > cash Flow > change In Working Capital
-15654000
Quarters > 1 > cash Flow > cash From Operations
-36447000
Quarters > 1 > cash Flow > capital Expenditures
4633500
Quarters > 1 > cash Flow > cash From Investing
8796500
Quarters > 1 > cash Flow > cash From Financing
4660500
Quarters > 1 > cash Flow > net Change In Cash
-
Quarters > 1 > ratios > PE
1.3034967466187686
Quarters > 1 > ratios > PB
1.9239436043200355
Quarters > 1 > ratios > ROE
18.508149290842464
Quarters > 1 > ratios > ROA
12.808822370125117
Quarters > 1 > ratios > FCF
-41080500
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
-0.2958869477846563
Quarters > 1 > health Score
73
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
162260000
Quarters > 2 > income Statement > cost Of Revenue
190429000
Quarters > 2 > income Statement > gross Profit
-28169000
Quarters > 2 > income Statement > operating Expenses
-20077000
Quarters > 2 > income Statement > operating Income
-8092000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
8156000
Quarters > 2 > income Statement > net Income
5964000
Quarters > 2 > income Statement > eps
0.03415323272774414
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
174624758
Quarters > 2 > income Statement > income Tax Expense
2153000
Quarters > 2 > income Statement > EBITDA
-5047000
Quarters > 2 > income Statement > operating Margin
-4.987057808455566
Quarters > 2 > income Statement > total Other Income Expense Net
16248000
Quarters > 2 > balance Sheet > cash
153958000
Quarters > 2 > balance Sheet > short Term Investments
682152000
Quarters > 2 > balance Sheet > receivables
167743000
Quarters > 2 > balance Sheet > inventories
50400000
Quarters > 2 > balance Sheet > total Current Assets
1066555000
Quarters > 2 > balance Sheet > property Plant Equipment
96995000
Quarters > 2 > balance Sheet > total Assets
1274196000
Quarters > 2 > balance Sheet > payables
42521000
Quarters > 2 > balance Sheet > short Term Debt
26297000
Quarters > 2 > balance Sheet > long Term Debt
59434000
Quarters > 2 > balance Sheet > total Liabilities
502343000
Quarters > 2 > balance Sheet > equity
759929000
Quarters > 2 > cash Flow > net Income
5964000
Quarters > 2 > cash Flow > depreciation
3044500
Quarters > 2 > cash Flow > change In Working Capital
-613000
Quarters > 2 > cash Flow > cash From Operations
20164500
Quarters > 2 > cash Flow > capital Expenditures
3912500
Quarters > 2 > cash Flow > cash From Investing
-45312500
Quarters > 2 > cash Flow > cash From Financing
947500
Quarters > 2 > cash Flow > net Change In Cash
-
Quarters > 2 > ratios > PE
0.03415323272774414
Quarters > 2 > ratios > PB
3.1136665016073874
Quarters > 2 > ratios > ROE
0.7848101598965167
Quarters > 2 > ratios > ROA
0.4680598589228031
Quarters > 2 > ratios > FCF
16252000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.10016023665721681
Quarters > 2 > health Score
52
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
162260000
Quarters > 3 > income Statement > cost Of Revenue
190429000
Quarters > 3 > income Statement > gross Profit
-28169000
Quarters > 3 > income Statement > operating Expenses
-20077000
Quarters > 3 > income Statement > operating Income
-8092000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
8156000
Quarters > 3 > income Statement > net Income
5964000
Quarters > 3 > income Statement > eps
0.03415323272774414
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
174624758
Quarters > 3 > income Statement > income Tax Expense
2153000
Quarters > 3 > income Statement > EBITDA
-5047000
Quarters > 3 > income Statement > operating Margin
-4.987057808455566
Quarters > 3 > income Statement > total Other Income Expense Net
16248000
Quarters > 3 > balance Sheet > cash
153958000
Quarters > 3 > balance Sheet > short Term Investments
684799000
Quarters > 3 > balance Sheet > receivables
155537000
Quarters > 3 > balance Sheet > inventories
50400000
Quarters > 3 > balance Sheet > total Current Assets
1066555000
Quarters > 3 > balance Sheet > property Plant Equipment
96995000
Quarters > 3 > balance Sheet > total Assets
1274196000
Quarters > 3 > balance Sheet > payables
42521000
Quarters > 3 > balance Sheet > short Term Debt
26297000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
502343000
Quarters > 3 > balance Sheet > equity
759929000
Quarters > 3 > cash Flow > net Income
5964000
Quarters > 3 > cash Flow > depreciation
3044500
Quarters > 3 > cash Flow > change In Working Capital
-613000
Quarters > 3 > cash Flow > cash From Operations
20164500
Quarters > 3 > cash Flow > capital Expenditures
3912500
Quarters > 3 > cash Flow > cash From Investing
-45312500
Quarters > 3 > cash Flow > cash From Financing
947500
Quarters > 3 > cash Flow > net Change In Cash
-203953000
Quarters > 3 > ratios > PE
0.03415323272774414
Quarters > 3 > ratios > PB
3.1136665016073874
Quarters > 3 > ratios > ROE
0.7848101598965167
Quarters > 3 > ratios > ROA
0.4680598589228031
Quarters > 3 > ratios > FCF
16252000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.10016023665721681
Quarters > 3 > health Score
52
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
630201000
Annuals > 0 > income Statement > cost Of Revenue
348884000
Annuals > 0 > income Statement > gross Profit
281317000
Annuals > 0 > income Statement > operating Expenses
321927000
Annuals > 0 > income Statement > operating Income
-43705000
Annuals > 0 > income Statement > interest Expense
2872000
Annuals > 0 > income Statement > pretax Income
45362000
Annuals > 0 > income Statement > net Income
37729000
Annuals > 0 > income Statement > eps
0.2161305364510116
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
174565800
Annuals > 0 > income Statement > income Tax Expense
7192000
Annuals > 0 > income Statement > EBITDA
14106000
Annuals > 0 > income Statement > operating Margin
-6.935088963679842
Annuals > 0 > income Statement > total Other Income Expense Net
89067000
Annuals > 0 > balance Sheet > cash
153958000
Annuals > 0 > balance Sheet > short Term Investments
682152000
Annuals > 0 > balance Sheet > receivables
167743000
Annuals > 0 > balance Sheet > inventories
50400000
Annuals > 0 > balance Sheet > total Current Assets
1066555000
Annuals > 0 > balance Sheet > property Plant Equipment
96995000
Annuals > 0 > balance Sheet > total Assets
1274196000
Annuals > 0 > balance Sheet > payables
42521000
Annuals > 0 > balance Sheet > short Term Debt
26297000
Annuals > 0 > balance Sheet > long Term Debt
59434000
Annuals > 0 > balance Sheet > total Liabilities
502343000
Annuals > 0 > balance Sheet > equity
759929000
Annuals > 0 > cash Flow > net Income
37729000
Annuals > 0 > cash Flow > depreciation
12341000
Annuals > 0 > cash Flow > change In Working Capital
-62169000
Annuals > 0 > cash Flow > cash From Operations
497000
Annuals > 0 > cash Flow > capital Expenditures
17933000
Annuals > 0 > cash Flow > cash From Investing
-96060000
Annuals > 0 > cash Flow > cash From Financing
-30667000
Annuals > 0 > cash Flow > net Change In Cash
-129631000
Annuals > 0 > ratios > PE
0.2161305364510116
Annuals > 0 > ratios > PB
3.312465817201344
Annuals > 0 > ratios > ROE
4.964805922658564
Annuals > 0 > ratios > ROA
2.961004429459832
Annuals > 0 > ratios > FCF
-17436000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
-0.027667363269813918
Annuals > 0 > health Score
49
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
837999000
Annuals > 1 > income Statement > cost Of Revenue
384447000
Annuals > 1 > income Statement > gross Profit
453552000
Annuals > 1 > income Statement > operating Expenses
436231000
Annuals > 1 > income Statement > operating Income
18375000
Annuals > 1 > income Statement > interest Expense
759000
Annuals > 1 > income Statement > pretax Income
105603000
Annuals > 1 > income Statement > net Income
100780000
Annuals > 1 > income Statement > eps
0.5797309237419769
Annuals > 1 > income Statement > dividends Per Share
123410000
Annuals > 1 > income Statement > shares Outstanding
173839269
Annuals > 1 > income Statement > income Tax Expense
4509000
Annuals > 1 > income Statement > EBITDA
67274000
Annuals > 1 > income Statement > operating Margin
2.1927233803381627
Annuals > 1 > income Statement > total Other Income Expense Net
87228000
Annuals > 1 > balance Sheet > cash
283589000
Annuals > 1 > balance Sheet > short Term Investments
602747000
Annuals > 1 > balance Sheet > receivables
150458000
Annuals > 1 > balance Sheet > inventories
50258000
Annuals > 1 > balance Sheet > total Current Assets
1096839000
Annuals > 1 > balance Sheet > property Plant Equipment
104392000
Annuals > 1 > balance Sheet > total Assets
1279773000
Annuals > 1 > balance Sheet > payables
36327000
Annuals > 1 > balance Sheet > short Term Debt
35082000
Annuals > 1 > balance Sheet > long Term Debt
48189000
Annuals > 1 > balance Sheet > total Liabilities
536386000
Annuals > 1 > balance Sheet > equity
730541000
Annuals > 1 > cash Flow > net Income
100780000
Annuals > 1 > cash Flow > depreciation
8207000
Annuals > 1 > cash Flow > change In Working Capital
71146000
Annuals > 1 > cash Flow > cash From Operations
219258000
Annuals > 1 > cash Flow > capital Expenditures
32612000
Annuals > 1 > cash Flow > cash From Investing
-291136000
Annuals > 1 > cash Flow > cash From Financing
48660000
Annuals > 1 > cash Flow > net Change In Cash
-29689000
Annuals > 1 > ratios > PE
0.5797309237419769
Annuals > 1 > ratios > PB
3.431377922635417
Annuals > 1 > ratios > ROE
13.795255844641163
Annuals > 1 > ratios > ROA
7.874834052601516
Annuals > 1 > ratios > FCF
186646000
Annuals > 1 > ratios > Piotroski FScore
4
Annuals > 1 > ratios > fcf Percent
0.22272818941311387
Annuals > 1 > health Score
79
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
426409000
Annuals > 2 > income Statement > cost Of Revenue
311103000
Annuals > 2 > income Statement > gross Profit
115306000
Annuals > 2 > income Statement > operating Expenses
522999000
Annuals > 2 > income Statement > operating Income
-409770000
Annuals > 2 > income Statement > interest Expense
652000
Annuals > 2 > income Statement > pretax Income
-360240449
Annuals > 2 > income Statement > net Income
-360835000
Annuals > 2 > income Statement > eps
-2.1297158212408727
Annuals > 2 > income Statement > dividends Per Share
87436000
Annuals > 2 > income Statement > shares Outstanding
169428708
Annuals > 2 > income Statement > income Tax Expense
-283000
Annuals > 2 > income Statement > EBITDA
-401106000
Annuals > 2 > income Statement > operating Margin
-96.09787785905081
Annuals > 2 > income Statement > total Other Income Expense Net
51518712
Annuals > 2 > balance Sheet > cash
313278000
Annuals > 2 > balance Sheet > short Term Investments
317718000
Annuals > 2 > balance Sheet > receivables
126723000
Annuals > 2 > balance Sheet > inventories
56690000
Annuals > 2 > balance Sheet > total Current Assets
839888000
Annuals > 2 > balance Sheet > property Plant Equipment
84669000
Annuals > 2 > balance Sheet > total Assets
1029445000
Annuals > 2 > balance Sheet > payables
71115000
Annuals > 2 > balance Sheet > short Term Debt
3708000
Annuals > 2 > balance Sheet > long Term Debt
18104000
Annuals > 2 > balance Sheet > total Liabilities
392575000
Annuals > 2 > balance Sheet > equity
610367000
Annuals > 2 > cash Flow > net Income
-360386000
Annuals > 2 > cash Flow > depreciation
8664000
Annuals > 2 > cash Flow > change In Working Capital
58704000
Annuals > 2 > cash Flow > cash From Operations
-268599000
Annuals > 2 > cash Flow > capital Expenditures
36664000
Annuals > 2 > cash Flow > cash From Investing
296588000
Annuals > 2 > cash Flow > cash From Financing
-82763000
Annuals > 2 > cash Flow > net Change In Cash
-64264000
Annuals > 2 > ratios > PE
-2.1297158212408727
Annuals > 2 > ratios > PB
4.002775329203577
Annuals > 2 > ratios > ROE
-59.11771114755548
Annuals > 2 > ratios > ROA
-35.05141119729563
Annuals > 2 > ratios > FCF
-305263000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-0.7158924881979508
Annuals > 2 > health Score
25
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
356128000
Annuals > 3 > income Statement > cost Of Revenue
258234000
Annuals > 3 > income Statement > gross Profit
97894000
Annuals > 3 > income Statement > operating Expenses
426211000
Annuals > 3 > income Statement > operating Income
-344288392
Annuals > 3 > income Statement > interest Expense
592000
Annuals > 3 > income Statement > pretax Income
-155328905
Annuals > 3 > income Statement > net Income
-194648000
Annuals > 3 > income Statement > eps
-1.2277772246643595
Annuals > 3 > income Statement > dividends Per Share
99744000
Annuals > 3 > income Statement > shares Outstanding
158536904
Annuals > 3 > income Statement > income Tax Expense
11918000
Annuals > 3 > income Statement > EBITDA
-207958000
Annuals > 3 > income Statement > operating Margin
-96.6754627549645
Annuals > 3 > income Statement > total Other Income Expense Net
188959487
Annuals > 3 > balance Sheet > cash
377542000
Annuals > 3 > balance Sheet > short Term Investments
634158000
Annuals > 3 > balance Sheet > receivables
147732000
Annuals > 3 > balance Sheet > inventories
35755000
Annuals > 3 > balance Sheet > total Current Assets
1212076000
Annuals > 3 > balance Sheet > property Plant Equipment
66323000
Annuals > 3 > balance Sheet > total Assets
1372661000
Annuals > 3 > balance Sheet > payables
41177000
Annuals > 3 > balance Sheet > short Term Debt
31822000
Annuals > 3 > balance Sheet > long Term Debt
0
Annuals > 3 > balance Sheet > total Liabilities
333147000
Annuals > 3 > balance Sheet > equity
986893000
Annuals > 3 > cash Flow > net Income
-167041000
Annuals > 3 > cash Flow > depreciation
7190000
Annuals > 3 > cash Flow > change In Working Capital
32458000
Annuals > 3 > cash Flow > cash From Operations
-204223000
Annuals > 3 > cash Flow > capital Expenditures
16756000
Annuals > 3 > cash Flow > cash From Investing
-306320000
Annuals > 3 > cash Flow > cash From Financing
650028000
Annuals > 3 > cash Flow > net Change In Cash
141912000
Annuals > 3 > ratios > PE
-1.2277772246643595
Annuals > 3 > ratios > PB
2.316464049983129
Annuals > 3 > ratios > ROE
-19.72331346964666
Annuals > 3 > ratios > ROA
-14.18034022967069
Annuals > 3 > ratios > FCF
-220979000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-0.620504425375146
Annuals > 3 > health Score
35
Valuation > metrics > PE
5.4415
Valuation > metrics > PB
1.9239436043200355
Valuation > final Score
100
Valuation > verdict
22.8% Undervalued
Profitability > metrics > ROE
18.508149290842464
Profitability > metrics > ROA
14.285821944864342
Profitability > metrics > Net Margin
1.6384288219766132
Profitability > final Score
97
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
0.434490799502711
Risk > metrics > Interest Coverage
-0.006808586491717899
Risk > final Score
60
Risk > verdict
High
Liquidity > metrics > Current Ratio
21.686441947565545
Liquidity > metrics > Quick Ratio
21.686441947565545
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
68.86333498392612
Prev Valuations > 2
68.86333498392612
Prev Profitabilities > 0
97
Prev Profitabilities > 1
9
Prev Profitabilities > 2
9
Prev Risks > 0
60
Prev Risks > 1
46
Prev Risks > 2
46
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T00:47:38.108Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-23
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-14
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
0
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-07
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
0.52
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
0.52
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-28
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
0
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-03-19
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
0.01
Earnings History > 4 > eps Estimate
0.04
Earnings History > 4 > eps Difference
-0.03
Earnings History > 4 > surprise Percent
-75
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-29
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
0
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-07-31
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
0
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-29
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
-
Earnings History > 7 > eps Actual
0
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-02-28
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.7
Earnings History > 8 > eps Estimate
-1.08
Earnings History > 8 > eps Difference
0.38
Earnings History > 8 > surprise Percent
35.1852
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-11-10
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
0
Earnings History > 9 > eps Estimate
0.04
Earnings History > 9 > eps Difference
-0.04
Earnings History > 9 > surprise Percent
-100
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-07-31
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
0.97
Earnings History > 10 > eps Estimate
-0.055
Earnings History > 10 > eps Difference
1.025
Earnings History > 10 > surprise Percent
1863.6364
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-31
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
0
Earnings History > 11 > eps Estimate
-0.05
Earnings History > 11 > eps Difference
0.05
Earnings History > 11 > surprise Percent
100
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-02-28
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
BeforeMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-1.02
Earnings History > 12 > eps Estimate
-1.02
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
0
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-11-11
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
0
Earnings History > 13 > eps Estimate
-0.7
Earnings History > 13 > eps Difference
0.7
Earnings History > 13 > surprise Percent
100
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-08-01
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
BeforeMarket
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-0.96
Earnings History > 14 > eps Estimate
-0.72
Earnings History > 14 > eps Difference
-0.24
Earnings History > 14 > surprise Percent
-33.3333
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-06-01
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
-0.7
Earnings History > 15 > eps Estimate
-0.7
Earnings History > 15 > eps Difference
0
Earnings History > 15 > surprise Percent
0
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-03-03
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
BeforeMarket
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
-0.29
Earnings History > 16 > eps Estimate
-0.73
Earnings History > 16 > eps Difference
0.44
Earnings History > 16 > surprise Percent
60.274
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-11-12
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
0
Earnings History > 17 > eps Estimate
-0.2419
Earnings History > 17 > eps Difference
0.2419
Earnings History > 17 > surprise Percent
100
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-07-28
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
BeforeMarket
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
-0.33
Earnings History > 18 > eps Estimate
-0.33
Earnings History > 18 > eps Difference
0
Earnings History > 18 > surprise Percent
0
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-06-02
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-0.3461
Earnings History > 19 > eps Estimate
-0.3581
Earnings History > 19 > eps Difference
0.012
Earnings History > 19 > surprise Percent
3.351
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2021-03-04
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
BeforeMarket
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
-0.2423
Earnings History > 20 > eps Estimate
-0.13
Earnings History > 20 > eps Difference
-0.1123
Earnings History > 20 > surprise Percent
-86.3846
Earnings History > 21 > period
2020-09-30
Earnings History > 21 > report Date
2020-11-13
Earnings History > 21 > date
2020-09-30
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
-0.1845
Earnings History > 21 > eps Estimate
-0.2052
Earnings History > 21 > eps Difference
0.0207
Earnings History > 21 > surprise Percent
10.0877
Earnings History > 22 > period
2020-06-30
Earnings History > 22 > report Date
2020-07-30
Earnings History > 22 > date
2020-06-30
Earnings History > 22 > before After Market
BeforeMarket
Earnings History > 22 > currency
USD
Earnings History > 22 > eps Actual
-0.2652
Earnings History > 22 > eps Estimate
-0.27
Earnings History > 22 > eps Difference
0.0048
Earnings History > 22 > surprise Percent
1.7778
Earnings History > 23 > period
2020-03-31
Earnings History > 23 > report Date
2020-06-03
Earnings History > 23 > date
2020-03-31
Earnings History > 23 > before After Market
-
Earnings History > 23 > currency
USD
Earnings History > 23 > eps Actual
-0.2652
Earnings History > 23 > eps Estimate
-0.32
Earnings History > 23 > eps Difference
0.0548
Earnings History > 23 > surprise Percent
17.125
Earnings History > 24 > period
2019-12-31
Earnings History > 24 > report Date
2020-03-03
Earnings History > 24 > date
2019-12-31
Earnings History > 24 > before After Market
BeforeMarket
Earnings History > 24 > currency
USD
Earnings History > 24 > eps Actual
-0.25
Earnings History > 24 > eps Estimate
-0.13
Earnings History > 24 > eps Difference
-0.12
Earnings History > 24 > surprise Percent
-92.3077
Earnings History > 25 > period
2019-09-30
Earnings History > 25 > report Date
2019-11-15
Earnings History > 25 > date
2019-09-30
Earnings History > 25 > before After Market
-
Earnings History > 25 > currency
USD
Earnings History > 25 > eps Actual
-0.1287
Earnings History > 25 > eps Estimate
-0.17
Earnings History > 25 > eps Difference
0.0413
Earnings History > 25 > surprise Percent
24.2941
Earnings History > 26 > period
2019-06-30
Earnings History > 26 > report Date
2019-07-30
Earnings History > 26 > date
2019-06-30
Earnings History > 26 > before After Market
BeforeMarket
Earnings History > 26 > currency
USD
Earnings History > 26 > eps Actual
-0.1547
Earnings History > 26 > eps Estimate
-0.15
Earnings History > 26 > eps Difference
-0.0047
Earnings History > 26 > surprise Percent
-3.1333
Earnings History > 27 > period
2019-03-31
Earnings History > 27 > report Date
2019-05-29
Earnings History > 27 > date
2019-03-31
Earnings History > 27 > before After Market
-
Earnings History > 27 > currency
USD
Earnings History > 27 > eps Actual
-0.1547
Earnings History > 27 > eps Estimate
-0.13
Earnings History > 27 > eps Difference
-0.0247
Earnings History > 27 > surprise Percent
-19
Earnings History > 28 > period
2018-12-31
Earnings History > 28 > report Date
2019-03-11
Earnings History > 28 > date
2018-12-31
Earnings History > 28 > before After Market
BeforeMarket
Earnings History > 28 > currency
USD
Earnings History > 28 > eps Actual
-0.16
Earnings History > 28 > eps Estimate
-0.06
Earnings History > 28 > eps Difference
-0.1
Earnings History > 28 > surprise Percent
-166.6667
Earnings History > 29 > period
2018-09-30
Earnings History > 29 > report Date
2018-11-16
Earnings History > 29 > date
2018-09-30
Earnings History > 29 > before After Market
-
Earnings History > 29 > currency
USD
Earnings History > 29 > eps Actual
-0.07
Earnings History > 29 > eps Estimate
-0.07
Earnings History > 29 > eps Difference
0
Earnings History > 29 > surprise Percent
0
Earnings History > 30 > period
2018-06-30
Earnings History > 30 > report Date
2018-07-27
Earnings History > 30 > date
2018-06-30
Earnings History > 30 > before After Market
AfterMarket
Earnings History > 30 > currency
USD
Earnings History > 30 > eps Actual
-0.14
Earnings History > 30 > eps Estimate
-0.16
Earnings History > 30 > eps Difference
0.02
Earnings History > 30 > surprise Percent
12.5
Earnings History > 31 > period
2018-03-31
Earnings History > 31 > report Date
2018-05-30
Earnings History > 31 > date
2018-03-31
Earnings History > 31 > before After Market
-
Earnings History > 31 > currency
USD
Earnings History > 31 > eps Actual
-0.14
Earnings History > 31 > eps Estimate
-0.16
Earnings History > 31 > eps Difference
0.02
Earnings History > 31 > surprise Percent
12.5
Earnings History > 32 > period
2017-12-31
Earnings History > 32 > report Date
2018-03-12
Earnings History > 32 > date
2017-12-31
Earnings History > 32 > before After Market
BeforeMarket
Earnings History > 32 > currency
USD
Earnings History > 32 > eps Actual
-0.12
Earnings History > 32 > eps Estimate
0.01
Earnings History > 32 > eps Difference
-0.13
Earnings History > 32 > surprise Percent
-1300
Earnings History > 33 > period
2017-06-30
Earnings History > 33 > report Date
2017-07-31
Earnings History > 33 > date
2017-06-30
Earnings History > 33 > before After Market
BeforeMarket
Earnings History > 33 > currency
USD
Earnings History > 33 > eps Actual
0.03
Earnings History > 33 > eps Estimate
0.09
Earnings History > 33 > eps Difference
-0.06
Earnings History > 33 > surprise Percent
-66.6667
Earnings History > 34 > period
2017-03-31
Earnings History > 34 > report Date
2017-05-31
Earnings History > 34 > date
2017-03-31
Earnings History > 34 > before After Market
-
Earnings History > 34 > currency
USD
Earnings History > 34 > eps Actual
0.01
Earnings History > 34 > eps Estimate
0
Earnings History > 34 > eps Difference
0.01
Earnings History > 34 > surprise Percent
-
Earnings History > 35 > period
2016-12-31
Earnings History > 35 > report Date
2017-03-13
Earnings History > 35 > date
2016-12-31
Earnings History > 35 > before After Market
AfterMarket
Earnings History > 35 > currency
USD
Earnings History > 35 > eps Actual
0.1
Earnings History > 35 > eps Estimate
-0.01
Earnings History > 35 > eps Difference
0.11
Earnings History > 35 > surprise Percent
1100
Earnings History > 36 > period
2016-09-30
Earnings History > 36 > report Date
2016-11-11
Earnings History > 36 > date
2016-09-30
Earnings History > 36 > before After Market
-
Earnings History > 36 > currency
USD
Earnings History > 36 > eps Actual
0.01
Earnings History > 36 > eps Estimate
0
Earnings History > 36 > eps Difference
0.01
Earnings History > 36 > surprise Percent
-
Earnings History > 37 > period
2016-06-30
Earnings History > 37 > report Date
2016-08-02
Earnings History > 37 > date
2016-06-30
Earnings History > 37 > before After Market
BeforeMarket
Earnings History > 37 > currency
USD
Earnings History > 37 > eps Actual
0.01
Earnings History > 37 > eps Estimate
-0.06
Earnings History > 37 > eps Difference
0.07
Earnings History > 37 > surprise Percent
116.6667
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AHCM Acquisition (NASDAQ:HCMA) Shares Down 0.1% - Here's What Happened MarketBeat
Read more →Further weakness as HUTCHMED (China) (LON:HCM) drops 7.0% this week, taking five-year losses to 53% simplywall.st
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
BUY
Target Price:
$22.5434
Analyst Picks
Strong Buy
9
Buy
2
Hold
3
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-06-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Medium
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very High
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 5.20% of the total shares of HUTCHMED DRC
1.
Schroder Investment Management Group(1.5008%)
since
2025/06/30
2.
Schroder Asian Growth SGD A Dis(0.5571%)
since
2025/05/31
3.
Allianz Asset Management AG(0.538%)
since
2025/06/30
4.
Schroder ISF Hong Kong Eq C Acc HKD(0.4688%)
since
2025/07/31
5.
Allianz Oriental Income P USD(0.3843%)
since
2025/07/31
6.
State Street Corp(0.1913%)
since
2025/06/30
7.
AIA Group Ltd(0.1835%)
since
2025/06/30
8.
Goldman Sachs Group Inc(0.1682%)
since
2025/06/30
9.
M&G PLC(0.1511%)
since
2025/06/30
10.
Jane Street Group LLC(0.1024%)
since
2025/06/30
11.
M&G Global Emerging Markets GBP I Acc(0.095%)
since
2025/05/31
12.
Amundi(0.0916%)
since
2025/06/30
13.
Renaissance Technologies Corp(0.0751%)
since
2025/06/30
14.
State St Gbl Sm Cp Eq ex-US Indx NL Cl A(0.0701%)
since
2025/08/31
15.
Catalyst Funds Management Pty Ltd(0.0639%)
since
2025/06/30
16.
BSO Bio Santé C(0.0582%)
since
2025/08/31
17.
Millennium Management LLC(0.0554%)
since
2025/06/30
18.
UBS Group AG(0.0375%)
since
2025/06/30
19.
ABN AMRO Investment Solutions(0.0372%)
since
2025/06/30
20.
SPDR® Portfolio Developed Wld ex-US ETF(0.036%)
since
2025/08/29
21.
AAF-M&G Emg Mkts ESG Equities C$(0.0349%)
since
2025/08/31
22.
Crossmark Global Holdings, Inc.(0.0296%)
since
2025/06/30
23.
Steward Values Enhanced International I(0.0291%)
since
2025/07/31
24.
Neos Investment Management, LLC(0.0248%)
since
2025/06/30
25.
Tema ETFs(0.0248%)
since
2025/06/30
26.
DekaBank Deutsche Girozentrale(0.0241%)
since
2025/06/30
27.
Tema Oncology ETF(0.0226%)
since
2025/08/29
28.
Citadel Advisors Llc(0.0218%)
since
2025/06/30
29.
M&G (Lux) Glb Em Mkts C USD Acc(0.0189%)
since
2025/05/31
30.
SPDR MSCI Emerging Markets SmallCap ETF(0.0166%)
since
2025/08/31
31.
Two Sigma Investments LLC(0.0161%)
since
2025/06/30
32.
BNP Paribas Arbitrage, SA(0.0146%)
since
2025/06/30
33.
Fidelity Nasdaq Composite Index(0.0127%)
since
2025/07/31
34.
State Street Glb All Cap Eq ex-US Idx(0.0123%)
since
2025/08/31
35.
iShares Nasdaq US Biotech ETF USD Acc(0.0103%)
since
2025/08/31
36.
Storebrand Emerging Markets A SEK(0.0054%)
since
2025/08/31
37.
Fullgoal Glb Healt Life Alloc(QDII)USD(0.005%)
since
2025/06/30
38.
Storebrand Global All Countries A SEK(0.0037%)
since
2025/08/31
39.
China Universal NASDAQ Bio-Tch ETF(QDII)(0.0036%)
since
2025/06/30
40.
National Security Emerging Mkts Idx ETF(0.0031%)
since
2025/08/29
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2025-09-30
EPS Actual
0
EPS Estimate
0
EPS Difference
0
Surprise Percent
null%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.